Medical Venture Varinos Completes Series D Fundraising Totaling Approximately 1.25 Billion Yen

Q: What are the key facts in this article?

Medical venture Varinos has completed a Series D fundraising round of approximately 1.25 billion yen. These funds will be used for improving the quality of its core uterine flora test, expanding its business both domestically and internationally, and developing new businesses, especially in women's health through a partnership with Mitsui Chemicals.

Q: What is the direct answer?

Medical venture Varinos has completed a Series D fundraising round of approximately 1.25 billion yen. These funds will be used for improving the quality of its core uterine flora test, expanding its business both domestically and internationally, and developing new businesses, especially in women's health through a partnership with Mitsui Chemicals.

Q: What is the source and date?

Source: https://prtimes.jp/main/html/rd/p/000000023.000054568.html | Date: Date unavailable

Varinos Co., Ltd. (Headquarters: Koto-ku, Tokyo; Chairman of the Board: Yoshiyuki Sakuraba; Representative Director CEO: Yoichi Saito; Representative Director President: Hidetoshi Hirakawa; hereinafter "Varinos"), which develops and clinically implements genetic testing using genome technology, is pleased to announce that it has completed a Series D fundraising round totaling approximately 1.25 billion yen. This round welcomed Mirai Sosei Investments Co., Ltd. as the lead investor, and Mitsui Chemicals, Inc. and Yokohama Capital Co., Ltd. as new investors. Debt financing was also secured from Resona Bank as the lead lender, along with Shizuoka Bank, Shoko Chukin Bank, Joyo Bank, and Higashi-Nippon Bank. Concurrently with this fundraising, Varinos has refreshed its management structure, with Yoshiyuki Sakuraba assuming the role of Chairman of the Board, Yoichi Saito as Representative Director CEO, and Hidetoshi Hirakawa as Representative Director President. Starting with a newly concluded research agreement with Mitsui Chemicals, Inc., Varinos aims to accelerate the development of new businesses, expand the domestic and international market share of its core business, uterine flora testing, and further improve the quality of uterine flora testing and other various tests. ◆ Background and Purpose of Fundraising ― Implementation of the core business "Uterine Flora Test" has grown approximately 3x in 2 years The "Uterine Flora Test," which Varinos commercialized for the first time in the world in 2017 to examine the bacterial environment within the uterus using genome analysis technology, has been introduced in over 400 medical institutions, primarily infertility treatment clinics *1, and the cumulative number of analyzed samples has exceeded 50,000 *2. Furthermore, in June 2022, it was certified as advanced medical technology as "Uterine Bacterial Flora Test 2," and its introduction and implementation in medical settings have progressed. Comparing fiscal years 2023 and

Medical Venture Varinos Completes Series D Fundraising Totaling Approximately 1.25 Billion Yen

AI Summary (NQ-processed)

AI Analysis